Format

Send to

Choose Destination
Blood. 2015 Nov 26;126(22):2484-90. doi: 10.1182/blood-2015-04-641100. Epub 2015 Oct 22.

Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia.

Author information

1
Section of Hematology/Oncology, Center for Clinical Cancer Genetics, The University of Chicago, Chicago, IL;
2
Siteman Cancer Center.
3
The Genome Institute, and.
4
Siteman Cancer Center, The Genome Institute, and Division of Oncology, Department of Medicine, Washington University, St Louis, MO;
5
Medimmune/AstraZeneca, Gaithersburg, MD;
6
Division of Oncology, Department of Medicine, Washington University, St Louis, MO;
7
Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD;
8
Department of Medicine, University of Minnesota, Minneapolis, MN; and.
9
Siteman Cancer Center, Division of Oncology, Department of Medicine, Washington University, St Louis, MO;
10
Siteman Cancer Center, The Genome Institute, and.
11
Massachusetts General Hospital Cancer Center, Boston, MA.

Abstract

Familial clustering of myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML) can be caused by inherited factors. We screened 59 individuals from 17 families with 2 or more biological relatives with MDS/AML for variants in 12 genes with established roles in predisposition to MDS/AML, and identified a pathogenic germ line variant in 5 families (29%). Extending the screen with a panel of 264 genes that are recurrently mutated in de novo AML, we identified rare, nonsynonymous germ line variants in 4 genes, each segregating with MDS/AML in 2 families. Somatic mutations are required for progression to MDS/AML in these familial cases. Using a combination of targeted and exome sequencing of tumor and matched normal samples from 26 familial MDS/AML cases and asymptomatic carriers, we identified recurrent frameshift mutations in the cohesin-associated factor PDS5B, co-occurrence of somatic ASXL1 mutations with germ line GATA2 mutations, and recurrent mutations in other known MDS/AML drivers. Mutations in genes that are recurrently mutated in de novo AML were underrepresented in the familial MDS/AML cases, although the total number of somatic mutations per exome was the same. Lastly, clonal skewing of hematopoiesis was detected in 67% of young, asymptomatic RUNX1 carriers, providing a potential biomarker that could be used for surveillance in these high-risk families.

PMID:
26492932
PMCID:
PMC4661171
DOI:
10.1182/blood-2015-04-641100
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center